AdvanSource Antimicrobial Polymers Targets Eradication of MRSA
Clinical Infections Associated with Medical Devices
AdvanSource Biomaterials Corporation (NYSE Alternext US: ASB), a
leading developer of advanced polymer materials for a broad range of
medical devices, announced today notification of the publication by the
U.S. Patent and Trademark Office of the Company’s U.S. patent
application related to antimicrobial polyurethane polymers.
The Company is developing a drug-free, antimicrobial technology to
eradicate MRSA clinical infections associated with medical devices. The
Company believes that infection rates from MRSA, primarily from
hospitals and other medical facilities, pose significant risks to
patient populations and are increasing in frequency.
The Patent Office is continuing its patent application review process
which typically takes 12-24 months to complete. Recent changes to U.S.
patent law relating to the publication of applications may entitle the
Company to provisional rights in the form of reasonable royalties from
the date of publication to the date the patent actually issues, although
there can be no assurance that a patent will be issued.
Dr. Andrew Reed, Vice President of Science and Technology stated: “Our
proprietary manufacturing process is differentiated by incorporating the
antimicrobial agent during the synthesis process. These antimicrobial
formulations are designed to possess a high degree of bacterial "kill."
The materials may be used as structural components or as coatings in
various catheters, including venus, arterial and urological.”
The Company’s antimicrobial polymers exhibit the following properties:
-
The surface of components manufactured from its antimicrobial polymers
are less susceptible to bacterial growth and biofilm formation,
reducing the potential for foreign body patient infections, and
-
The antimicrobial agent is uniformly dispersed throughout the polymer,
providing long lasting activity.
About AdvanSource Biomaterials Corporation
AdvanSource Biomaterials Corporation manufactures advanced polymer
materials which provide critical characteristics in the design and
development of medical devices. The Company’s biomaterials are used in
devices that are designed for treating a broad range of anatomical sites
and disease states. AdvanSource’s business model leverages its
proprietary materials science technology and manufacturing expertise in
order to expand its product sales and royalty and license fee income.
The Company is conducting a clinical trial for regulatory approval at
two sites in Europe for its CardioPass™ synthetic coronary bypass graft.
More information about AdvanSource is available at its website: www.advbiomaterials.com
Forward-Looking Statements:
AdvanSource believes that this press release contains forward-looking
statements as that term is defined in the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements are subject
to risks and uncertainties. Such statements are based on
management’s current expectations and are subject to risks and
uncertainties that could cause results to differ materially from the
forward-looking statements. For further information on such risks
and uncertainties, you are encouraged to review AdvanSource’s filings
with the Securities and Exchange Commission, including its Annual Report
on Form 10-K for the fiscal year ended March 31, 2008 and its Quarterly
Reports for the periods ended June 30, 2008 and September 30, 2008. AdvanSource
assumes no obligation to update any forward-looking statements as a
result of new information or future events or developments, except as
required by law.
AdvanSource Biomaterials
Eric Walters, 978-657-0075
Vice
President & CFO
info@advbiomaterials.com
or
VMW
Corporate & Investor Relations
Sylvia Dresner, 212-616-6161
Senior
Vice President
info@vmwcom.com
